

STATUS OF THE CLAIMS

1.-16. Cancelled.

17. (Currently Amended) A method of treating viral or bacterial infections, inflammatory diseases, or a tumor, said method comprising:

- (a) administering a pharmaceutical composition ~~comprising~~ consisting essentially of a pharmaceutically effective amount of isolated granzyme B as the only pharmaceutically active component to cells affected by said infection or inflammatory diseases or tumor cells, said target cells bearing Hsp70 on their surface;
- (b) allowing granzyme B to enter said cells via ~~ion channels formed by said~~ Hsp70 on the surface of said cells; and
- (c) allowing said cells to undergo apoptosis as a result of the enzymatic activity of granzyme B.

18-24. (Cancelled).

25. (Previously Amended) The method of claim 17, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1µg/ml to 500µg/ml.

26. (Previously Amended) The method of claim 17, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1ng/ml to 10 ng/ml.

27. (Previously Amended) The method of claim 26 wherein granzyme B is present in the pharmaceutical composition in a final concentration of about 6 ng/ml.

28. (Previously Presented) The method of claim 17, wherein the viral infection is an infection by HIV or Hepatitis virus.

29. (Currently amended) A method of treating viral or bacterial infections, inflammatory diseases or a tumor, said method comprising:

- (a) analyzing target cells of a patient for surface expression of Hsp70;
- (b) administering a pharmaceutical composition comprising a pharmaceutically effective amount of ~~isolated~~ granzyme B ~~as the only pharmaceutically active component~~ to cells affected by said infection or inflammation or tumor cells, said cells bearing Hsp70 on their surface;
- (c) allowing granzyme B to enter said cells via ~~ion channels formed by~~ Hsp70 on the cell surface; and
- (d) allowing said cells to undergo apoptosis as a result of the enzymatic activity of granzyme B, ~~wherein said cells affected by said infection or inflammation or tumor cells are analyzed for surface expression of Hsp70.~~
30. (Previously Presented) The method of claim 29, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1 μ g/ml to 500 μ g/ml.
31. (Previously Presented) The method of claim 29, wherein granzyme B is present in the pharmaceutical composition in a final concentration of 1ng/ml to 10 ng/ml.
32. (Previously Presented) The method of claim 31 wherein granzyme B is present in the pharmaceutical composition in a final concentration of about 6 ng/ml.
33. (Previously Presented) The method of claim 29, wherein the viral infection is an infection by HIV or Hepatitis virus.